Anticorps Polyclonal de lapin anti-ESRP2

ESRP2 Polyclonal Antibody for WB, IHC, ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, souris

Applications

WB, IHC, ELISA

Conjugaison

Non conjugué

Publications(1)

N° de cat : 23117-1-AP

Synonymes

ESRP2, RBM35B, RNA binding motif protein 35B, RNA binding protein 35B

---

Galerie de données de validation

• 

  WB analysis using 23117-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 23117-1-AP (ESRP2 antibody) at dilution of 1:300 incubated at room temperature for 1.5 hours.

• 

  WB analysis using 23117-1-AP

  Various lysates were subjected to SDS PAGE followed by western blot with 23117-1-AP (ESRP2 antibody) at dilution of 1:1500 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human breast cancer using 23117-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 23117-1-AP (ESRP2 antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human breast cancer using 23117-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 23117-1-AP (ESRP2 antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human breast cancer using 23117-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 23117-1-AP (ESRP2 antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human breast cancer using 23117-1-AP

  Immunohistochemical analysis of paraffin-embedded human breast cancer tissue slide using 23117-1-AP (ESRP2 antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Applications testées

• Résultats positifs en WB: cellules A431, cellules HeLa, cellules HepG2
• Résultats positifs en IHC: tissu de cancer du sein humain, ; il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0.

Dilution recommandée

• Western Blot (WB): WB : 1:200-1:1000
• Immunohistochimie (IHC): IHC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Informations sur le produit

23117-1-AP cible ESRP2 dans les applications de WB, IHC, ELISA et montre une réactivité avec des échantillons Humain, souris

• Réactivité: Humain, souris
• Réactivité citée: Humain
• Hôte / Isotype: Lapin / IgG
• Clonalité: Polyclonal
• Type: Anticorps
• Immunogène: ESRP2 Protéine recombinante Ag19436
• Nom complet: epithelial splicing regulatory protein 2
• Masse moléculaire calculée: 727 aa, 78 kDa
• Poids moléculaire observé: 78 kDa
• Numéro d’acquisition GenBank: BC030146
• Symbole du gène: ESRP2
• Identification du gène (NCBI): 80004
• Conjugaison: Non conjugué
• Forme: Liquide
• Méthode de purification: Purification par affinité contre l'antigène
• Tampon de stockage: PBS with 0.02% sodium azide and 50% glycerol
• Conditions de stockage: Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20^oC Les 20ul contiennent 0,1% de BSA.

Informations générales

ESRP2 (Epithelial Splicing Regulatory Protein 2), also known as RBM35B(RNA binding motif protein 35B), is a member of the heterogeneous nuclear ribonucleoprotein (hnRNP) family of RNA binding proteins. ESRP2 plays a role in the regulation of alternative splicing events of pre-mRNAs(PMID: 27401076). Overexpression of ESRP2 has been described in various malignant tumors, such as pancreatic ductal adenocarcinoma, oral squamous carcinoma, ovarian cancer, and luminal-type breast cancer(PMID: 33339518).

Publications

Species	Application	Title
human		Oncogene; Androgen receptor signaling regulates the transcriptome of prostate cancer cells by modulating global alternative splicing.; Authors - Kalpit Shah

{{ptg:RelatedPrimaryAntibodies}}